FindTrial
Sign In

Bone Marrow Aspiration/Biopsy

PROCEDURE4 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Aggressive B-cell Lymphoma With Secondary Involvement of the CNSCutaneous T-Cell LymphomaFollicular LymphomaHematologic MalignanciesLymphoid MalignanciesLymphomaMature T-cell MalignanciesNHL

Phase 1

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
CompletedNCT04447027
National Cancer Institute (NCI)Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma +1
Start: 2020-12-17End: 2025-12-17Updated: 2026-01-30
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
Active, not recruitingNCT05211336
National Cancer Institute (NCI)Aggressive B-cell Lymphoma With Secondary Involvement of the CNS, Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
Start: 2022-04-19End: 2029-06-01Updated: 2026-01-08
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
CompletedNCT05371054
National Cancer Institute (NCI)Hematologic Malignancies, Lymphoid Malignancies, Lymphoma +2
Start: 2023-04-05End: 2025-12-16Updated: 2026-02-23

Phase 2

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Active, not recruitingNCT03789240
National Cancer Institute (NCI)Follicular Lymphoma, NHL, Non-Hodgkin's Lymphoma
Start: 2019-08-22End: 2027-01-01Updated: 2026-03-03

Related Papers

Romidepsin, Azacitidine, Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-Cell Lymphoma
Blood2024-11-052 citations
Abstract PO-007: A phase 1 study of romidepsin, azacitidine, dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignancies
Blood Cancer Discovery2024-06-19
Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma
Blood2023-11-021 citations
Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma
Blood2020-11-041 citations